| Hormone refractory prostate cancer
Provenge vs Xofigo
Side-by-side clinical, coverage, and cost comparison for hormone refractory prostate cancer.Deep comparison between: Provenge vs Xofigo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXofigo has a higher rate of injection site reactions vs Provenge based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xofigo but not Provenge, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Provenge
Xofigo
At A Glance
IV infusion
Every 2 weeks
Autologous cellular immunotherapy
IV injection
Every 4 weeks
Alpha particle-emitting radiopharmaceutical
Indications
- Hormone refractory prostate cancer
- Hormone refractory prostate cancer
Dosing
Hormone refractory prostate cancer 3 complete doses at approximately 2-week intervals; each dose infused IV over approximately 60 minutes; premedicate with acetaminophen and antihistamine approximately 30 minutes prior to infusion.
Hormone refractory prostate cancer 55 kBq (1.49 microcurie) per kg body weight by slow IV injection over 1 minute, every 4 weeks for 6 injections.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Chills, fatigue, fever, back pain, nausea, joint ache, headache
Serious Acute infusion reactions, cerebrovascular events, eosinophilia, rhabdomyolysis, myasthenia gravis, myositis, tumor flare
Postmarketing Syncope, transient ischemic attack, strokes, hypotension, myocardial infarction, deep venous thrombosis, pulmonary embolism
Most common (>=10%) Nausea, diarrhea, vomiting, peripheral edema; hematologic: anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia.
Serious Bone marrow suppression.
Pharmacology
PROVENGE is an autologous cellular immunotherapy designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers; APCs are activated ex vivo with the PAP-GM-CSF fusion protein, take up and process the recombinant antigen, and display it on the cell surface to stimulate T cell and antibody responses.
Radium-223 mimics calcium and forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover such as bone metastases; the high linear energy transfer of alpha particles leads to a high frequency of double-strand DNA breaks in adjacent tumor cells, resulting in an anti-tumor effect on bone metastases.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Provenge
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Xofigo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Provenge
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xofigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Provenge
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Xofigo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ProvengeView full Provenge profile
XofigoView full Xofigo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.